In July 2014, we entered into a license agreement (the “Genzyme Agreement”) with Genzyme Corporation ("Genzyme"), a wholly owned subsidiary of Sanofi, pursuant to which we were granted an exclusive l…
We also have a license agreement with Abbisko Therapeutics Co. Ltd. ("Abbisko"), which granted Abbisko the exclusive right to perform regulatory activities on, manufacture and distribute mavorixafor …
On January 13, 2025, we announced a license and supply agreement (the “Norgine Agreement”) with Norgine, pursuant to which Norgine was granted an exclusive license to distribute, market and sell our …
In February 2025, we announced that we had entered into an agreement with Taiba Middle East Fz LLC ("taiba rare") to distribute and commercialize XOLREMDI for the treatment of WHIM syndrome in select…
X4 Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
XFOR-DEBT-13657
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-12-31.
XFOR-DEBT-13656
Warrants outstanding: 15241246
90%
xbrl warrant detail from xbrl 2025-12-31.
XFOR-DEBT
Debt stack $77.3M
90%
Market cache reports total debt of $77.3M.
X4 Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for X4 Pharmaceuticals, Inc..
X4 Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
XFOR-OWNER-MORGAN-STANLEY
MORGAN STANLEY
90%
13F overlay lists MORGAN STANLEY as top holder; 82 tracked holders.
X4 Pharmaceuticals, Inc. Extended Supply Chain Network
